Products - Bladder cancer | Topic | NICE

Showing 6 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 February 2025
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 June 2025
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC